AEON Biopharma

AEON

Market cap $9.78M

- Meeting date aligns with prior guidance - - FDA to review AEON's analytical development plan and initial data - IRVINE, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a biopharmaceutical company developing ABP-450 (prabotulinumtoxinA) as a BOTOX® (onabotulinumtoxinA) biosimilar, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Biosimilar Biological Product Development (BPD) Type 2a meeting for ABP-450 on November 19, 2025, in line with prior guidance.

– Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q'25 – – Type 2a meeting with the FDA anticipated in 4Q'25– – Cash runway expected to support operations through FDA meeting and regulatory feedback – IRVINE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a biopharmaceutical company seeking an accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX® (onabotulinumtoxinA) biosimilar, announced its financial results for the second quarter ended June 30, 2025, and provided a business update.

IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today reported the grant in May of 102,880 restricted stock units (RSUs) of the Company's common stock to newly hired non-executive employees of the company. The awards were approved by the Company's Board of Directors under the AEON 2025 Inducement Incentive Plan, which a grant date and vesting commencement date of May 21, 2025.

IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Rob Bancroft, AEON's President and Chief Executive Officer, will present a corporate overview at the Aegis Capital Corp. 2025 Virtual Conference on Wednesday, May 21st at 7:00 a.m. PT / 10:00 am ET.

– Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 –

IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today it has received notification (the “Acceptance Letter”) from the NYSE American LLC (“NYSE American”) that NYSE American has accepted the Company's previously submitted plan (the “Plan”) to regain compliance with NYSE American's continued listing standards set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide (the “Company Guide”) relating to minimum market capitalization and stockholders' equity.

IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that, in connection with the appointment of Rob Bancroft as President and Chief Executive Officer, the Company's Compensation Committee of the Board of Directors has approved the grant of inducement awards.

– Former CEO, Marc Forth, to remain as a member of the Company's Board of Directors – – Former CEO, Marc Forth, to remain as a member of the Company's Board of Directors –

– Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors – – Jost Fischer, Chairman of AEON, will assume the role of interim CEO – IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today a leadership transition under which Marc Forth is stepping down as President and Chief Executive Officer of the Company to pursue another opportunity, effective April 4, 2025.

– Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 –